Health ConditionsSeasonal affective disorder (SAD) is a type of depression characterized by a recurrent seasonal pattern, with symptoms lasting about 4–5 months out of the year. Within the natural-health and nutritional context, the broader concept of seasonal mood support encompasses not only the clinical diagnosis of SAD but also its subsyndromal form and the spectrum of seasonal shifts in mood, energy, appetite, and sleep that many people experience with changing light conditions.
SAD is a recurrent major depressive disorder with a seasonal pattern usually beginning in fall and continuing into winter months. A subsyndromal type of SAD, or S-SAD, is commonly known as "winter blues." A milder form of seasonal disorder, the winter blues, yields similar symptoms of decreased energy and increased appetite and can also affect enthusiasm and productivity, but to a lesser extent.
Recognized as a subtype of major depressive disorder and bipolar disorder, SAD typically presents with major depressive episodes in the fall or winter and alleviates by spring or summer. This condition transcends transient sadness, profoundly influencing mood, cognitive function, and physical health.
In most cases, SAD symptoms start in the late fall or early winter and go away during the spring and summer, known as winter-pattern SAD or winter depression. Other people experience depressive symptoms during the spring and summer months, known as summer-pattern SAD or summer depression. Summer-pattern SAD is less common.
The symptom profile of winter-pattern SAD is distinctive and differs from typical major depression in several characteristic ways:
Negative thoughts and feelings about the winter or summer and its associated limitations and stresses are also common among people with SAD. It is unclear, however, whether these thoughts are causes or effects of the mood disorder, but they can be a useful focus of attention.
At the core of seasonal affective disorder lies the disruption of the circadian rhythm — the internal biological clock that regulates the sleep-wake cycle, hormone release, and body temperature. The sleep-wake cycle and the endogenous circadian rhythm are best when they are in sync, according to the "phase-shift hypothesis," the current leading theory for the etiology of SAD. As the days become shorter in autumn and winter, the natural body clock begins to advance in relation to the time of day and the sleep-wake cycle. There is speculation that this phase difference contributes to emotional distress.
Studies assessing seasonal physiological changes associated with SAD have reported the dampening and possible loss of rhythmicity of daily melatonin patterns, decreased diurnal cortisol levels, and a drop in serotonin levels in the winter. In vivo seasonal amplitude and phase differences in circadian gene oscillations have been observed in individuals reporting SAD symptoms. Individuals who reported stronger seasonality symptoms experienced lower amplitudes of rhythms throughout the year than those who reported not being SAD-susceptible.
Studies indicate that people with SAD, especially winter-pattern SAD, have reduced levels of the brain chemical serotonin, which helps regulate mood. A drop in serotonin, a brain chemical (neurotransmitter) that affects mood, might play a role in SAD. Reduced sunlight can cause a drop in serotonin that may trigger depression.
Seasonal changes affect the natural light-dark cycle, causing a phase shift of the circadian clock that alters neurotransmitter release (particularly serotonin), functions of neural circuits, melatonin, and cortisol rhythm.
The circadian rhythm is fueled by the secretion of melatonin from the pineal gland in response to darkness. Whereas melatonin induces sleep, the hormone serotonin produces energy and feelings of happiness, and increases with exposure to bright light. Individuals who have seasonal affective disorder show a longer duration of melatonin release during nights and winter months, due to shorter daylight hours.
In a typical neurological profile, the duration of melatonin secretion corresponds to the length of the night. However, in seasonal affective disorder, the secretion curve becomes elongated or delayed.
Dopamine governs the brain's reward and motivation pathways. The lethargy, lack of focus, and anhedonia — the inability to feel pleasure — associated with seasonal depression are linked to downregulated dopamine activity. The interaction between the circadian clock and dopamine synthesis is complex, but evidence indicates that retinal light exposure influences dopamine release. When light is scarce, the drive to seek rewards diminishes, contributing to the withdrawal and behavioral inactivity often observed in patients.
Leading hypotheses supporting direct connections between clock genes and mood include the monoamine hypothesis and the retinal sub-sensitivity hypothesis. The monoamine hypothesis suggests a direct influence of circadian-regulated transcription factors on multiple monoaminergic brain regions via modulation of dopamine, serotonin, and/or norepinephrine pathways.
The retinal subsensitivity hypothesis posits that individuals with SAD have less sensitive light input pathways, leading to differences in neurobiological responses related to circadian photoentrainment and melatonin release. Light therapy applied to the popliteal fossa in the knee of individuals with SAD was demonstrated to have no impact on symptoms, suggesting that the therapeutic benefits of light therapy seem to require the eyes and light-activated retinofugal pathways.
Sunlight plays a critical role in decreased serotonin activity, increased melatonin production, disrupted circadian rhythms, and low levels of vitamin D associated with symptoms of SAD. With less outdoor exposure to sunlight on the skin in winter, people with SAD may produce less vitamin D. As vitamin D is believed to play a role in serotonin activity, vitamin D deficiency and insufficiency have been associated with clinically significant depressive symptoms.
SAD's prevalence increases with distance from the equator, suggesting a link to environmental light exposure. Overall, seasonal affective disorder is a mood disorder with a prevalence that varies between 1.5% and 10%. Higher latitudes tend to have higher prevalence rates, but populations around the world may be affected by SAD to some extent. Environmental risk factors mainly center around photoperiod (day length) and light exposure, which have been shown to affect physiological circadian and infradian (e.g., seasonal) cycles, gene expression, and sleep.
Since the syndrome is linked to a lack of light, people with SAD may become depressed during cloudy weather at any time of year, or if they are confined to windowless offices or basement apartments.
Susceptibility to seasonal affective disorder is not randomly distributed; it shows clear familial aggregation, suggesting a genetic component. Variations in genes controlling the circadian clock and serotonin transport have been implicated. With a heritability of up to 29% across its behavioral dimensions, there is a substantial genetic component to SAD, one that is similar in size to that of major depressive disorder (35%) but lower than bipolar disorder (70–90%).
SAD's prevalence in the general population can be as high as 4–15%, and SAD is four times more prevalent in women. Demographic analysis reveals that this condition is diagnosed more frequently in women than in men and often manifests in early adulthood. The reasons for the gender disparity are still being investigated, but may involve interactions between sex hormones and the circadian system. Age also plays a role, as the prevalence tends to decrease with age, potentially due to age-related changes in retinal sensitivity or sleep requirements.
Those most at risk are female, are younger, live far from the equator, and have family histories of depression, bipolar disorder, or SAD.
Seasonal affective disorder is a biological and mood disorder with a seasonal pattern. Dietary intervention and nutritional status have been reported to affect SAD severity. Eleven studies were included in one systematic review: six examined distinctive dietary patterns and eating behaviors in SAD patients, and five explored the efficacy of nutrition interventions for SAD. Vegetarianism and alcoholism were associated with higher SAD prevalence, but normal alcohol intake was not correlated with SAD severity.
Compared with non-clinical subjects, SAD patients tended to consume significantly larger dinners and more evening snacks during weekdays and weekends and exhibit a higher frequency of binge eating and external eating.
Traditional/Historical Use: Vitamin D is not a traditional herbal remedy but a fat-soluble nutrient synthesized endogenously through sun exposure. Its association with seasonal health follows naturally from the observation that populations at northern latitudes receive less UVB radiation in winter and consequently produce less vitamin D. Interest in its role in mood arose from ecological observations long predating controlled trials.
Scientific Evidence: Low blood levels of vitamin D are often found in people with SAD; however, the evidence for its use has been mixed. Although some studies suggest vitamin D supplementation may be as effective as light therapy, others found vitamin D had no effect.
Specific clinical trial data from NCCIH include the following:
Seasonal affective disorder is associated with insufficient sunlight exposure and vitamin D deficiency. Vitamin D supplementation for SAD shows inconsistent results due to methodological variations. At present, vitamin D supplementation by itself is not considered an effective SAD treatment. Evidence strength: Preliminary and mixed; small sample sizes limit conclusions.
Traditional/Historical Use: Dietary fish-eating traditions in Nordic, Japanese, and Arctic populations, where oily fish constituted a staple food, are sometimes cited as an ecological basis for interest in omega-3 fatty acids and mood. No formal traditional medicinal use for seasonal mood specifically is well-documented in herbal monograph sources.
Scientific Evidence: The changing of omega-6/omega-3 polyunsaturated fatty acids (PUFAs) in the food supply of Western societies over the last 150 years is thought to promote the pathogenesis of many inflammatory-related diseases, including depressive disorders. Several epidemiological studies reported a significant inverse correlation between intake of oily fish and depression or bipolar disorders.
The existing body of evidence demonstrates that omega-3 fatty acids, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have antidepressant effects that can be attributed to their modulation of neuroinflammation, neurotransmitter function, and neuroplasticity. Nevertheless, clinical trials of omega-3 supplementation have yielded inconsistent results.
Clinical studies revealed that subjects diagnosed with depression or anxiety display significantly lower levels of omega-3 PUFAs and higher ratios of omega-6 to omega-3 PUFAs in the blood and in the brain.
Most meta-analyses confirmed a statistically significant effect in favor of omega-3 fatty acids, with minimal to moderate effect sizes depending on the selection of studies. Two double-blind clinical studies out of four blinded clinical trials did not demonstrate a reduction in clinical scores. In one trial, the administration of 350 mg of EPA and 50 mg of DHA three times per day for 8 weeks improved the mood of treated female patients.
Based on the outcomes of clinical studies, systematic reviews, and meta-analyses, it can be concluded that the impact of omega-3 intake on the course of depression can be varied. Whereas some authors highlight the clinical effectiveness of these nutrients, others provide evidence that such therapy has no health benefits, at least in relation to mood. Note that the literature cited above focuses on depression broadly; specific trial data targeting SAD populations with omega-3 supplementation specifically remains limited. Evidence strength: Moderate for general depression; preliminary and indirect for seasonal-specific mood.
Traditional Use: St. John's wort (Hypericum perforatum), a plant that grows in the wild, has been used for centuries for mental health conditions. It is widely prescribed for depression in Europe. Historically, the plant was used in European folk medicine not only for mood complaints but also for wounds, burns, and nerve pain. Its bright-yellow flowers, blooming at midsummer around the feast of St. John (June 24), gave the herb its common name; dried flowering tops were the traditional preparation form.
Scientific Evidence: Like pharmaceutical antidepressants, St. John's wort is thought to raise levels of neurotransmitters in the brain, such as serotonin, norepinephrine, and dopamine. The active ingredient of St. John's wort is not known. Extracts are most often standardized to the substance hypericin, which has led to the widespread misconception that hypericin is the active ingredient. However, there is no evidence that hypericin itself is an antidepressant. Another ingredient, hyperforin, has shown considerable promise as the most important ingredient.
For SAD specifically, an uncontrolled open trial by Wheatley (1999) found no significant difference in SAD score improvements resulting from H. perforatum alone versus combined H. perforatum and light therapy. Beyond depression, St. John's wort has been explored for treating conditions like SAD, although the evidence for its efficacy in these areas remains mixed.
For general depression, the evidence is more substantial but still contested: numerous clinical trials and meta-analyses assessing the efficacy of H. perforatum for the alleviation of mild to moderate depression report that extracts are significantly superior to placebo, similarly effective as standard antidepressant drugs, and produce significantly fewer side-effects than synthetic preparations. However, two studies sponsored by NCCIH and the National Institute of Mental Health did not have positive results: neither St. John's wort nor a standard antidepressant medication decreased symptoms of minor depression better than a placebo in a 2011 study, and the herb was no more effective than placebo in treating major depression of moderate severity in a large 2002 study.
St. John's wort is not a proven therapy for depression. Study results on the effectiveness of St. John's wort for depression are not conclusive. Evidence strength: Moderate for mild-to-moderate general depression; weak and methodologically limited for SAD specifically.
Traditional/Historical Use: Melatonin is an endogenous neurohormone rather than a traditional plant medicine. Its supplemental use is a modern development arising from the identification of its role in circadian regulation in the 1970s and later. Melatonin is an indoleamine primarily synthesized from tryptophan in the pineal gland through a multi-step enzymatic pathway.
Scientific Evidence: There is some limited evidence (small trials involving few patients) that suggests melatonin improves sleep in patients with SAD; however, no definite conclusions about its effectiveness can be made. Melatonin has mixed evidence, requiring further study. Evidence strength: Preliminary; insufficient evidence for firm conclusions specific to SAD mood outcomes.
Traditional/Historical Use: L-Tryptophan is an essential amino acid found in dietary protein (eggs, cheese, turkey, fish, oats, nuts, and seeds). Its role in serotonin biosynthesis is established biochemistry rather than a formal traditional herbal tradition. Interest in tryptophan supplementation for mood dates to the 1970s–1980s when it was sold as an over-the-counter supplement before a contaminated batch caused an outbreak of eosinophilia-myalgia syndrome in 1989, leading to a period of restricted availability in the US.
Scientific Evidence: The amino acid L-tryptophan has been implicated in the development of depression and shown to exert antidepressant effects. Tryptophan is among the promising products for depressive symptoms in the broader nutraceutical literature. Evidence strength: Mechanistically plausible; clinical evidence for SAD-specific use is limited, and most data relate to broader depressive disorders.
Traditional/Historical Use: B vitamins are not traditional herbal remedies but micronutrients recognized as essential for neurological function. Interest in their role in mood regulation is grounded in biochemistry: folate and B12 are required for homocysteine metabolism and methylation reactions that produce neurotransmitters.
Scientific Evidence: B vitamins are crucial for neurological function and mood regulation. Deficiencies in these vitamins are linked to depression. Studies on individual B vitamins show promise in improving depressive symptoms, particularly thiamin, riboflavin, niacin, and folate.
Abnormal levels of folate, homocysteine, and SAMe have been shown to be associated with a higher risk of depression. Numerous studies have demonstrated antidepressant activity with L-methylfolate and SAMe supplementation in individuals with depression. Deficiencies in vitamins B12, folate, or vitamin D are linked to elevated risk and occurrence of depression. Evidence strength: Moderate for deficiency-related depressive symptoms generally; minimal specific trial data for SAD populations.
Traditional/Historical Use: Magnesium is an essential mineral rather than a herbal medicine. It has been used empirically in complementary health contexts for muscle relaxation and stress reduction.
Scientific Evidence: Magnesium is among the agents with evidence for improving depressive symptoms. Magnesium has mixed evidence, requiring further study. Population survey data suggest associations between lower dietary magnesium and mood-related symptoms, but intervention trials specific to SAD are lacking. Evidence strength: Weak to preliminary for mood; no rigorous SAD-specific trial data identified.
Traditional Use: Saffron (Crocus sativus L.) stigmas have been used for millennia in Persian, Ayurvedic, and Mediterranean traditional medicine as a culinary spice and medicinal agent. In Persian traditional medicine, saffron was historically employed for low mood, melancholy, and menstrual complaints. Its use in traditional systems predates any scientific investigation by centuries.
Scientific Evidence: Studies have reinforced the hypothesis that saffron may exert antidepressant effects similar to selective serotonin reuptake inhibitors (SSRIs). In a six-week RCT (n=40), saffron petal extract (30 mg/day) was found to be significantly more effective than placebo in reducing Hamilton Depression Rating Scale (HAM-D) scores (p<0.001), suggesting that various parts of the plant may possess mood-enhancing properties.
However, a 2024 randomized double-blind placebo-controlled trial in healthy adults with subclinical symptoms found mixed results: saffron extract did not significantly affect the primary outcome of combined depressive, anxiety, and fatigue symptoms, nor individual symptoms. However, it improved autoperceived mental health as reflected in mental health scores over time compared with placebo.
Despite encouraging clinical and mechanistic findings, saffron remains underutilized in clinical practice. Challenges include the lack of long-term safety data, standardization difficulties, variability in extract composition, and limited regulatory oversight. Note that published saffron studies address general depression and subclinical depressive symptoms; no clinical trial data specific to SAD were identified. Evidence strength: Preliminary to moderate for general mild-to-moderate depression; SAD-specific evidence absent.
The largest volume of evidence exists for omega-3s, St. John's wort, saffron, probiotics, and vitamin D, all of which are relatively established products. However, a multitude of other products are promising, including folic acid, lavender, zinc, tryptophan, rhodiola, and lemon balm. These should be considered exploratory; rigorous clinical evidence for each in a seasonal-mood context is lacking.
Dietary intervention and nutritional status have been reported to affect SAD severity. The evidence from a systematic review examined associations between SAD and diet, eating behavior, and nutritional intervention. Vegetarianism and alcoholism were associated with higher SAD prevalence, but normal alcohol intake was not correlated with SAD severity.
Bright light therapy (BLT) and pharmacological therapies currently represent the first-line treatments for patients with SAD. Lifestyle modifications offer a diverse field of additional intervention options. A 2024 systematic review searched specifically for RCTs assessing lifestyle modifications — including nutrition, exercise, staying outdoors, sleep, social aspects, and mindfulness — in SAD patients.
Pronounced carbohydrate craving is a well-described feature of winter-pattern SAD. Energy level decreases, individuals tend to eat more, especially sweets and starches, and they gain weight. This pattern is believed to reflect altered serotonin regulation, as carbohydrate intake influences tryptophan availability and therefore serotonin synthesis, though this relationship is complex and not fully established in the SAD literature.
Research indicates that consistent exercise routines enhance serotonin levels and improve overall mood regulation, making physical activity a valuable adjunct to light therapy. Physical activity is frequently discussed in the broader seasonal depression literature as a behavioral intervention that may help offset reduced outdoor light exposure and support neurotransmitter balance, though rigorous RCT evidence for exercise specifically in SAD populations is limited.
Depression is the consequence of both environment and genes working together. Genetic factors increase depression risk, but it is unclear whether this association can be offset by time spent in outdoor light. Large observational studies, including data from the UK Biobank, have investigated the dose-response relationship between outdoor light and depression risk. Light therapy, as a structured intervention, is recognized as a first-line approach for SAD: a meta-analysis revealed that phototherapy was significantly more effective than other intervention groups or control therapies, with an effect size of 4.64.
SAD patients show advanced sleep phase syndrome (ASPS) and delayed sleep phase disorder/syndrome (DSPS). Regularizing sleep and wake times is discussed in clinical literature as a practical measure to support circadian alignment. Social rhythms — regular mealtimes, physical activity schedules, and social engagement — are considered non-photic zeitgebers (time-givers) that may help stabilize the biological clock.
Shift work and social jetlag groups are at higher risk for depression, with unfixed light patterns potentially contributing. This finding is relevant in a seasonal context because individuals with irregular light exposure schedules may be especially vulnerable to circadian disruption during shorter days.
Overall, seasonal affective disorder is a mood disorder with a prevalence that varies between 1.5% and 10%. Prevalence of SAD varies by both definition and region (1–16%), with higher prevalences observed for broader criteria such as subsyndromal SAD, and in regions at higher latitudes. In a survey conducted in the United Kingdom, the prevalence of SAD was found to be 10.7% based on the Seasonal Pattern Assessment Questionnaire (SPAQ). Even when assessed according to DSM-IV criteria, the prevalence still reached 5.6%.
An estimated 10 to 20 percent of recurrent depression cases follow a seasonal pattern. The relationship between latitude and SAD is not entirely straightforward. The relationship between prevalence of these disorders and geographic latitude is more complex than has previously been suggested; genetic adaptation in Icelandic populations may play an important role.
5-HTP is the immediate precursor to serotonin, a neurotransmitter central to mood regulation. SAD is associated with reduced serotonin activity in winter, providing mechanistic rationale for 5-HTP supplementation. A double-blind NIMH study examined neuroendocrine responses to 200 mg oral 5-HTP in ten SAD patients versus controls. Multiple small clinical trials and open-label studies support modest antidepressant effects, though efficacy for SAD specifically is considered preliminary by NCCIH.
Catecholamine depletion studies demonstrate a specific link between reduced tyrosine availability and mood worsening in seasonal affective disorder (SAD). One study showed tyrosine boosted winter mood scores while placebo subjects declined sharply. The photoperiod-dependent sensitivity of the dopamine system provides a plausible mechanistic basis.
Cod liver oil addresses two converging drivers of seasonal mood decline: vitamin D deficiency (which peaks in winter) and omega-3 insufficiency. Large observational studies link CLO use with lower rates of depression in populations with limited winter sunlight. Seasonal affective disorder involves both nutrient deficiencies.
DHA is the primary structural omega-3 fatty acid in neuronal membranes and is specifically reported to be reduced in patients with seasonal winter affective disorder alongside EPA. While EPA drives more of the acute antidepressant effect in RCTs, DHA supports neuronal membrane fluidity, serotonin receptor density, and brain health relevant to seasonal mood. It is co-identified in studies documenting omega-3 deficits in SAD populations.
Omega-3 PUFAs including DHA have been studied in seasonal and broader mood disorders. Lower omega-3 status correlates with more severe seasonal affective disorder symptoms in observational data. DHA's effects on serotonin, neuroinflammation, and HPA axis regulation provide a mechanistic basis for seasonal mood support.
EPA's antidepressant mechanism is relevant to seasonal affective disorder (SAD) and seasonal mood decline, as SAD shares neuroinflammatory and serotonergic dysregulation pathways EPA targets. Clinical data are primarily extrapolated from EPA's broader antidepressant evidence base, with specific SAD investigation limited.
EPA is the omega-3 fatty acid most consistently linked to antidepressant effects in meta-analyses of RCTs and is specifically reported to be reduced in patients with seasonal winter affective disorder. Meta-analyses identify EPA (not DHA) as primarily responsible for omega-3 antidepressant efficacy. It acts via serotonin receptor sensitization and neuroinflammation suppression. Clinical doses of 1–2 g/day EPA have shown benefit for depressive mood in controlled trials.
Fish oil omega-3s have been investigated for seasonal affective disorder (SAD) given the established links between omega-3 status, mood regulation, serotonin metabolism, and inflammatory pathways implicated in depressive disorders. Population-level data show higher fish consumption correlates with lower rates of depression including seasonal forms. While specific SAD RCTs are limited, the broader antidepressant evidence base supports seasonal mood applications.
L-Tryptophan is an essential amino acid and the dietary precursor to serotonin, whose brain turnover is lowest in winter and directly correlated with sunlight duration. A published clinical trial directly compared L-tryptophan to placebo and evening light in 13 SAD sufferers, finding both L-tryptophan and light produced greater improvement than placebo. A 2015 PubMed review concluded that activation of serotonin synthesis with L-tryptophan alone or combined with light therapy could be effective in SAD.
Clinical trials of oral lavender oil preparation Silexan demonstrate significant antidepressant effects, including in mixed anxiety-depressive disorder. A meta-analysis found significant antidepressant effects of lavender in seven out of ten eligible trials. Silexan at 80 mg/day showed comparable efficacy to sertraline 50 mg/day in mild-to-moderate major depression.
A 2021 meta-analysis of 8 RCTs (n=569) found that lemon balm significantly reduced depression scores (SMD: −0.47) versus placebo. GABAergic, serotonergic (MAO-A inhibition), and cholinergic mechanisms underpin mood effects. While no trial has specifically targeted seasonal affective disorder, the herb's mood-lifting and anti-depressant effects in clinical trials are directly relevant to seasonal mood dips.
Magnesium is an essential mineral involved in over 300 enzyme reactions including serotonin synthesis, NMDA receptor regulation, and HPA axis stress response—all relevant to seasonal mood. Multiple peer-reviewed reviews and RCTs document magnesium's anxiolytic and antidepressant properties. A 2017 RCT (n=126) found 248 mg/day magnesium significantly reduced PHQ-9 depression scores. It is consistently listed among supplements relevant to mood disorders including SAD-related presentations.
Melatonin is a pineal hormone regulating circadian rhythms and sleep-wake cycles, both disrupted in SAD. The duration of nocturnal melatonin secretion increases in winter, and abnormal melatonin secretion has been observed in SAD patients. NCCIH specifically lists melatonin among complementary approaches reviewed for SAD, noting limited evidence that it improves sleep in SAD patients. It is also hypothesized as a chemical mediator of photoperiodic effects on seasonal mood.
Omega-3 fatty acids (EPA and DHA) are specifically reported to be reduced in the blood of patients with seasonal winter affective disorder. They modulate serotonin availability, neuronal membrane fluidity, and anti-inflammatory pathways implicated in mood. Small RCTs and epidemiological studies show mixed but occasionally positive results for general depression, with direct evidence of deficiency in SAD populations. EPA at 1–2 g/day is most consistently linked to antidepressant effects.
Rhodiola rosea is an adaptogenic plant traditionally used in Scandinavia and Russia for fatigue and depression, conditions associated with northern winters. It modulates serotonin, dopamine, norepinephrine, and beta-endorphins in mood-relevant brain regions. A 12-week RCT (n=57) found depression improvement comparable to sertraline. A systematic review of two RCTs (n=146) and seven open-label studies (n=714) concluded possible antidepressant action. It is specifically identified as relevant to stress-induced and lethargic/asthenic depression patterns that overlap with SAD.
Saffron (Crocus sativus) stigma extracts have been studied in more than 20 RCTs for mild-to-moderate depression. Meta-analyses confirm saffron significantly improves depressive symptoms versus placebo and shows comparable efficacy to pharmaceutical antidepressants. Its active constituents (crocin, safranal) modulate serotonin reuptake and reduce neuroinflammation. The largest RCT to date (n=128+, 2025) confirmed clinically significant improvements in depressive symptoms. Standard clinical dose is 30 mg/day of standardized extract.
SAMe is a naturally occurring methyl donor involved in serotonin and dopamine metabolism in the brain. It has been marketed in Europe as an antidepressant since the mid-1980s. A Cochrane review confirms SAMe has antidepressant efficacy; multiple RCTs support its use as both monotherapy and SSRI augmentation. It is specifically listed by pharmacist-oriented clinical sources among supplements studied for seasonal mood and SAD due to its role in neurotransmitter optimization.
Sceletium's serotonergic mechanism—SERT inhibition and monoamine release—is directly relevant to seasonal affective disorder (SAD), which is treated clinically with SSRIs and light therapy. No clinical trial has specifically evaluated sceletium in SAD patients, but the mechanistic parallel with established SAD pharmacotherapy supports this link.
St. John's Wort (Hypericum perforatum) has been directly studied in SAD clinical trials. A 1994 study (n=20) found significant reductions in depressive symptoms with Hypericum plus light therapy, and a 1999 RCT (n=168) found improvements with Hypericum alone comparable to Hypericum combined with light therapy. NCCIH acknowledges limited but present evidence for symptom improvement in SAD. Standardized extract is typically dosed at 300 mg (0.3% hypericin) three times daily.
Low serum vitamin D levels are commonly found in people with SAD and are directly associated with reduced sunlight exposure in winter. NCCIH explicitly lists vitamin D among complementary approaches studied for SAD. A 1999 trial (n=15) found vitamin D comparable to phototherapy; however, a 2014 RCT (n=34) and a 2006 RCT (n=2,117) failed to show significant benefit. Evidence is mixed, and NCCIH does not currently support vitamin D alone as an effective SAD treatment.
Vitamin D3 (cholecalciferol) is the endogenous form of vitamin D produced in skin via UVB and the primary supplemental form studied for SAD. Reduced winter sunlight causes declining vitamin D3 production, and low serum 25(OH)D is consistently associated with SAD. Clinical evidence parallels that for vitamin D broadly: mixed results across RCTs, with NCCIH not currently supporting D3 monotherapy as an effective SAD treatment.
Cocoa has a long traditional use as a mood-elevating food, especially during low-mood periods. Chocolate craving during winter months is culturally recognized, and cocoa contains neuroactive compounds (phenylethylamine, theobromine, serotonin precursors) that may support mood seasonally. Specific RCTs for seasonal mood disorder have not been conducted.
Damiana is used traditionally as a mood-lifter and mild antidepressant, and preclinical data show relevant neurochemical activity including MAO-B inhibition, dopamine reuptake inhibition, and anxiolytic effects. These mechanisms are relevant to seasonal mood changes. No seasonal affective disorder-specific studies exist.
Geranium EO is used in aromatherapy for mood elevation and emotional balance, including seasonal affective states. Its uplifting, antidepressant, and stress-reducing properties are recognized in herbal medicine. Evidence is extrapolated from RCTs on anxiety and depression rather than from seasonal mood-specific trials.
Ginkgo biloba has a long history of use in traditional Chinese medicine for supporting mental vitality, clarity, and emotional wellbeing across seasonal transitions. Modern interest stems from its monoamine-modulating properties and neuroprotective effects. However, dedicated clinical trials for seasonal mood support or seasonal affective disorder specifically are lacking.
Kanna's documented traditional role as a mood elevator and its SERT-inhibiting mechanism (directly relevant to seasonal affective disorder pharmacotherapy, which relies on SSRIs) provide a plausible but unvalidated basis for seasonal mood support. No clinical studies have specifically assessed kanna for seasonal affective disorder or winter mood changes.
Go back